LITERATURE SEARCH NatHER meta-analysis

Transcription

1 LITERATURE SEARCH NatHER meta-analysis SEARCH Date of search: September 4 th 2014 Search strategy Step MEDLINE Results 1 (her2-positive or her2 positive).mp (HER2+ or HER2 positive).mp exp *Receptor, erbb-2/ or erb-2.mp epidermal growth factor receptor-2.m_titl epidermal growth factor receptor-2.mp exp *Receptor, Epidermal Growth Factor/ or epidermal growth factor receptor 2.mp or 2 or 3 or 4 or 5 or exp Breast Neoplasms/ exp Breast/ or Breast Diseases/ Neoplasms/ or Adenocarcinoma/ or Carcinoma/ (brca or (breast adj4 (adenocarcinoma* or cancer* or carcinoma* or metasta* or neoplasm* or tumo?r))).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier] 12 8 or 9 or 10 or metasta*.mp metastatic.mp. or exp *Neoplasm Metastasis/ secondary.mp spread.mp spreads.mp advanced.mp stage 4.mp stage IV.mp. or exp *Neoplasm Staging/ stage-iv.mp. or exp *Neoplasm Staging/ stage-4.mp or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or AND exp *Survival Analysis/ or exp *Survival/ or exp *Survival Rate/ or survival.mp progression-free survival.mp. or exp *Disease-Free Survival/ mortality.mp. or exp *Mortality/ death.mp. or exp *Death/ or 26 or 27 or randomized controlled trial.pt controlled clinical trial.pt randomized controlled trial.sh random allocation.sh double blind method.sh single blind method.sh

2 36 clinical trial.pt exp clinical trial/ (clin$ adj25 trial$).ti,ab ((singl$ OR doubl$ OR trebl$ OR tripl$) adj25 (blind$ OR mask$)).ti,ab placebos.sh placebo$.ti,ab random$.ti,ab research design.sh comparative study.sh exp evaluation studies/ follow up studies.sh prospective studies.sh (control$ OR prospectiv$ OR volunteer$).ti,ab OR/ Epidemiologic studies/ exp case control studies/ exp cohort studies/ Case control.tw (cohort adj (study or studies)).tw Cohort analy$.tw (Follow up adj (study or studies)).tw (observational adj (study or studies)).tw Longitudinal.tw Retrospective.tw Cross sectional.tw Cross-sectional studies/ OR/ #49 or # AND and 63 and limit 65 to humans limit 66 to English limit 67 to yr="1986 -Current"

3 EMBASE: ( Step EMBASE 1 her2 AND positive 'her2 positive' 'receptor erbb 2' 59 4 'erb 2' 'epidermal growth factor receptor 2' 'receptor epidermal growth factor' #1 or #2 or #3 or #4 or #5 or # breast AND neoplasms 'breast neoplasms' 'breast diseases' breast* breast AND (adenocarcinoma* OR cancer* OR carcinoma* OR metasta* OR neoplasm* OR tumo?r) breast AND (adenocarcinoma* OR cancer* OR breast AND tumor* OR breast AND tumour*) #8 or #9 or #10 or #11 or #12 or # metasta* metastatic 'neoplasm metastasis' secondary spread spreads OR advanced 'stage 4' OR 'stage-4' OR 'stage iv' OR 'stage-iv' OR 'neoplasm staging' #15 or #16 or #17 or #18 or #19 or #20 or # #14 AND # survival AND analysis 'survival analysis' 'survival/' OR 'survival rate/' OR 'survival' 'progression-free survival' OR 'progression free survival' 'disease-free survival' OR 'disease free survival' 'mortality' OR 'mortality/' 'death' OR 'death/' #24 or #25 or #26 or #27 or #28 or #29 or # clinical AND trial 'clinical trial'/exp 'randomized controlled trial'/exp 'randomization'/exp 'single blind procedure'/exp 'double blind procedure'/exp 'crossover procedure'/exp 'placebo'/exp randomized AND controlled AND trial$ rct.tw OR 'rct' randomised AND controlled AND trial$ random AND allocation randomly AND allocated 'allocated randomly' 'single blind$' 'double blind$' 'placebo$' 'prospective study'/exp

4 50 #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or # 'clinical study'/exp 'case control study' 'family study'/exp 'longitudinal study'/exp 'retrospective study'/exp 'prospective study'/exp 'randomized controlled trials'/exp #56 NOT # 'cohort analysis'/exp 'cohort study' 'cohort studies' 'cohort analysis' 'case control study' OR 'case control studies' 'observational study' OR 'observational studies' 'epidemiologic$ study' OR 'epidemiologic$ studies' 'cross sectional study' OR 'cross sectional studies' #51 or #52 or #53 or #54 or #55 or #58 or #59 or #60 or #61 or #62 or 67 #63 or #64 or #65 or # #50 or # #7 AND # #31 AND #68 AND # #70 AND [humans]/lim #71 AND [english]/lim #72 AND [ ]/py

5 CENTRAL: ( Step CENTRAL 1 "Her2" or "HER-2" or "HER2-neu" or "her2/neu" or "Her2/neu" or 950 "HER2/neu" or "Her-2-neu" or "HER-2-neu" or "her-2-neu" or "Her- 2/neu" or "HER-2/neu" or "her-2/neu" or "Her-2neu" or "HER-2neu" or "her-2neu" or "Her2neu" or "HER2neu" or "her2neu" 2 "erb2 receptor" or "epidermal growth factor receptor" or "epidermal 1309 growth factor" 3 #1 or # MeSH descriptor: [Breast Neoplasms] explode all trees 'breast neoplasms' 'breast diseases' breast* breast and (adenocarcinoma* or cancer* or carcinoma* or metasta* or neoplasm* or tumo?r) 9 breast and (adenocarcinoma* or cancer* or breast and tumor* or breast and tumour*) 10 #4 or #5 or #6 or #7 or #8 or # MeSH descriptor: [Neoplasm Metastasis] explode all trees "metasta*" or "metastatic" or "neoplasm metastasis" or "secondary" or "spread" or "spreads" or "advanced" 13 "stage 4" or "stage-4" or "stage iv" or "stage-iv" or "neoplasm staging" #11 or #12 or # #10 and # MeSH descriptor: [Survival Analysis] explode all trees "survival analysis" or "survival/" or "survival rate/" or "survival" MeSH descriptor: [Disease-Free Survival] explode all trees "disease-free survival" or "disease free survival" "progression-free survival" or "progression free survival" MeSH descriptor: [Mortality] explode all trees MeSH descriptor: [Death] explode all trees #16 or #17 or #18 or #19 or #20 or #21 or # #3 and # #23 and # Publication Year from 1987 to #hits per database: MEDLINE: 1527 EMBASE: 3970 CENTRAL: 377 Total: 5874 potentially relevant references identified with 1149 duplicate references Post de-duplication: MEDLINE: 1527 EMBASE: 3062 CENTRAL: 136 Total: 4725 potentially relevant references after excluding 1149 duplicate references 5

6 Author: Bindu Kalesan, PPDI Date: September 05, 2014 Checked by: 6